Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elisabetta Viscardi is active.

Publication


Featured researches published by Elisabetta Viscardi.


The American Journal of Surgical Pathology | 2011

Nonsense Mutation and Inactivation of SMARCA4 (BRG1) in an Atypical Teratoid/Rhabdoid Tumor Showing Retained SMARCB1 (INI1) Expression

Martin Hasselblatt; Stefan Gesk; Florian Oyen; Sabrina Rossi; Elisabetta Viscardi; Felice Giangaspero; Caterina Giannini; Alexander R. Judkins; Michael C. Frühwald; Tobias Obser; Reinhard Schneppenheim; Reiner Siebert; Werner Paulus

Atypical teratoid/rhabdoid tumors (AT/RTs) are highly aggressive brain tumors of early childhood poorly responding to therapy. The majority of cases show inactivation of SMARCB1 (INI1, hSNF5, BAF47), a core member of the adenosine triphosphate (ATP)-dependent SWI/SNF chromatin-remodeling complex. We here report the case of a supratentorial AT/RT in a 9-month-old boy, which showed retained SMARCB1 staining on immunohistochemistry and lacked genetic alterations of SMARCB1. Instead, the tumor showed loss of protein expression of another SWI/SNF chromatin-remodeling complex member, the ATPase subunit SMARCA4 (BRG1) due to a homozygous SMARCA4 mutation [c.2032C>T (p.Q678X)]. Our findings highlight the role of SMARCA4 in the pathogenesis of SMARCB1-positive AT/RT and the usefulness of antibodies directed against SMARCA4 in this diagnostic setting.


Journal of Clinical Oncology | 2010

Improved Survival of Children With Neuroblastoma Between 1979 and 2005: A Report of the Italian Neuroblastoma Registry

Riccardo Haupt; Alberto Garaventa; Claudio Gambini; Stefano Parodi; Giuliana Cangemi; Fiorina Casale; Elisabetta Viscardi; M. Bianchi; Arcangelo Prete; Alessandro Jenkner; Roberto Luksch; Andrea Di Cataldo; Claudio Favre; Paolo D'Angelo; Giulio Andrea Zanazzo; Giampaolo Arcamone; Gian Carlo Izzi; Anna Rita Gigliotti; Guido Pastore; Bruno De Bernardi

PURPOSE To describe treatment, clinical course, and survival of a cohort of Italian patients with neuroblastoma. PATIENTS AND METHODS The study includes data from 2,216 children (age 0 to 14 years) diagnosed between 1979 and 2005. Overall survival (OS) was analyzed by clinical and biologic features at presentation and periods of diagnosis: 1979 to 1984, 1985 to 1991, 1992 to 1998, and 1999 to 2005. The relative risk of second malignant neoplasm (SMN) was assessed by the standardized incidence ratio (SIR), with the Italian population selected as referent. RESULTS Yearly patient accrual increased over time from 58 to 102. Patients age 0 to 17 months represented 45.6% of the total population, and their incidence increased over time from 36.5% to 48.5%. The incidence of stage 1 patients increased over time from 5.8% to 23.2%. A total of 898 patients (40.5%) developed disease progression or relapse, 19 patients developed SMN, and two patients developed myelodysplasia. The cumulative risk of SMN at 20 years was 7.1%, for an SIR of 8.4 (95% CI, 5.1 to 13.2). A total of 858 patients (39%) died (779 of disease, 71 of toxicity, six of SMN, and two of tumor-unrelated surgical complications). Ten-year OS was 55.3% (95% CI, 53.0% to 57.6%) and increased over time from 34.9% to 65.0%; it was significantly better for females and patients age 0 to 17 months at diagnosis, with extra-abdominal primary, and stage 1 and 2 disease. OS improved significantly over time in stage 1 and 3 patients. In patients with stage 4 disease, the improvement occurred between the first and second time cohorts (6.7% v 23.5%), but not afterward. CONCLUSION The outcome of children with neuroblastoma has progressively improved. Long-term survivors bear a significant risk of SMN.


Neuro-oncology | 2007

Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program

Paola Dalla Via; Enrico Opocher; Maria Luisa Pinello; Milena Calderone; Elisabetta Viscardi; Maurizio Clementi; Pier Antonio Battistella; Anna Maria Laverda; Liviana Da Dalt; Giorgio Perilongo

We evaluated the visual outcome of a cohort of children with neurofibromatosis type 1 (NF1) and optic pathway glioma (OPG) treated according to standardized therapeutic guidelines. The study population consisted of all consecutive patients with NF1 and OPG referred to a specialized pediatric neuro-oncology program between 1994 and 2004. Treatment was instituted only in cases of progressive disease or clinical deterioration. Treatment modalities were chemotherapy (based on vincristine/carboplatin) for children younger than 5 years and radiotherapy for all others. Ten boys and 10 girls (seven with a positive family history) entered the trial (median age at diagnosis of OPG, 29 months). At a median follow-up time of 78 months, seven patients had been treated with chemotherapy only, four with radiotherapy, and four with chemotherapy plus radiotherapy. Five patients were observed only. Currently, 18 are alive and two have died. Eight patients were treated for progressive visual loss in the face of stable disease, five for tumor volume increase without visual deterioration, and two for symptomatic tumor volume increase. At referral, six children had a visual acuity (VA) of < 30% in both eyes; eight children had 100% VA bilaterally. At referral, the visual field (VF) could be assessed in three children: One had VF loss in both eyes, one had VF loss in one eye, and one had normal VF. At last follow-up, eight children had VA < 20% in both eyes; only two children had 100% VA in both eyes. Among 11 children who had some visual function, three had VF loss in one eye and three in both eyes, and five had an intact VF. Contrast and color sensitivity were abnormal in seven and six patients, respectively. Thirteen children fell into the WHO hypovision category. In summary, among the 15 children treated, one had a definitive and two a mild improvement in VA. In conclusion, the visual outcome of this selected cohort of NF1 patients with OPG is unsatisfactory. A critical reappraisal of the therapeutic strategy adopted is needed.


Cancer | 2006

Neuroblastoma in adolescents : The Italian experience

Massimo Conte; Stefano Parodi; Bruno De Bernardi; Claudia Milanaccio; Katia Mazzocco; Paola Angelini; Elisabetta Viscardi; Andrea Di Cataldo; Roberto Luksch; Riccardo Haupt

Neuroblastoma (NB) occurs rarely during adolescence, and information is scarce on its characteristics and clinical course in this age group.


European Journal of Cancer | 2009

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry

Alberto Garaventa; Stefano Parodi; Bruno De Bernardi; Daniela Dau; Carla Manzitti; Massimo Conte; Fiorina Casale; Elisabetta Viscardi; Maurizio Bianchi; Paolo D’Angelo; Giulio Andrea Zanazzo; Roberto Luksch; Claudio Favre; Angela Tamburini; Riccardo Haupt

The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relapse (P<0.001). Probability of survival increased by era of diagnosis. Survival of children with recurrent neuroblastoma is very poor. A small cohort of patients, mainly represented by children with stages 1 and 2 who underwent local recurrence or developed late relapse may still benefit from further conventional treatment. For the remaining larger proportion of patients, experimental therapies should be proposed.


Pediatric Blood & Cancer | 2010

Optic pathway glioma: Long-term visual outcome in children without neurofibromatosis type-1†

Marta Campagna; Enrico Opocher; Elisabetta Viscardi; Milena Calderone; Savina Maria Severino; Iveta Cermakova; Giorgio Perilongo

Little is known about the visual outcome of children affected by an optic pathway glioma (OPG).


Acta Neuropathologica | 2014

SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis.

Martin Hasselblatt; Inga Nagel; Florian Oyen; Kerstin Bartelheim; Robert B. Russell; Ulrich Schüller; Reimar Junckerstorff; Marc K. Rosenblum; Ali H. Alassiri; Sabrina Rossi; Irene Schmid; Nicholas G. Gottardo; Helen Toledano; Elisabetta Viscardi; Milagros Balbin; Leora Witkowski; Qianhao Lu; Matthew J. Betts; William D. Foulkes; Reiner Siebert; Michael C. Frühwald; Reinhard Schneppenheim

Martin Hasselblatt · Inga Nagel · Florian Oyen · Kerstin Bartelheim · Robert B. Russell · Ulrich Schuller · Reimar Junckerstorff · Marc Rosenblum · Ali H. Alassiri · Sabrina Rossi · Irene Schmid · Nicholas G. Gottardo · Helen Toledano · Elisabetta Viscardi · Milagros Balbin · Leora Witkowski · Qianhao Lu · Matthew J. Betts · William D. Foulkes · Reiner Siebert · Michael C. Fruhwald · Reinhard Schneppenheim


Pediatric Blood & Cancer | 2006

Evaluation of health status and health-related quality of life in a cohort of Italian children following treatment for a primary brain tumor.

Chiara Cardarelli; Cinzia Cereda; Lucia Masiero; Elisabetta Viscardi; Roberto Faggin; A. M. Laverda; Gianni Bisogno; Giorgio Perilongo

This study is a pilot experience aiming to investigate the compliance of an institutional cohort of Italian children treated for a malignant disease and their families in completing the health utilities index2, (HUI2) and the effectiveness of this measured in terms of their health status (HS) and health‐related quality of life (HRQL). It specifically, it aimed to compare the HS and the HRQL, as expressed by the HUI2 global utility score, in cohorts of patients who had brain tumors, extra‐cerebral solid tumors, or leukemia/lymphoma.


International Journal of Radiation Oncology Biology Physics | 2011

Infant Ependymoma in a 10-Year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) Experience With Omitted or Deferred Radiotherapy

Maura Massimino; Lorenza Gandola; Salvina Barra; Felice Giangaspero; Cecilia Casali; Paolo Potepan; Concezio Di Rocco; Paolo Nozza; Paola Collini; Elisabetta Viscardi; Daniele Bertin; Veronica Biassoni; Armando Cama; Claudia Milanaccio; Piergiorgio Modena; Rita Balter; Giampiero Tamburrini; Paola Peretta; Maurizio Mascarin; Giovanni Scarzello; Paola Fidani; Giuseppe Maria Milano; Iacopo Sardi; Lorenzo Genitori; Maria Luisa Garrè

PURPOSE The protocols of the 1990s omitted or delayed irradiation, using upfront chemotherapy to spare the youngest children with ependymoma the sequelae of radiotherapy (RT). We treated 41 children under the age of 3 years with intracranial ependymoma between 1994 and 2003. PATIENTS AND METHODS After surgery, chemotherapy was given as follows: regimen I with four blocks of vincristine, high-dose methotrexate 5 g/m(2), and cyclophosphamide 1.5 g/m(2) alternating with cisplatin 90 mg/m(2) plus VP16 450 mg/m(2) for 14 months; subsequently, regimen II was used: VEC (VCR, VP16 300 mg/m(2), and cyclophosphamide 3 g/m(2)) for 6 months. Radiotherapy was planned for residual tumor after the completion of chemotherapy or for progression. RESULTS We treated 23 boys and 18 girls who were a median 22 months old; 14 were given regimen I, 27 were given regimen II; 22 underwent complete resection, 19 had residual tumor. Ependymoma was Grade 2 in 25 patients and Grade 3 in 16; tumors were infratentorial in 37 patients and supratentorial in 4. One child had intracranial metastases; 29 had progressed locally after a median 9 months. Event-free survival was 26% at 3 and 5 years and 23% at 8 years. One child died of sepsis, and another developed a glioblastoma 72 months after RT. Progression-free survival was 27% at 3, 5, and 8 years, and overall survival was 48%, 37%, and 28% at 3, 5, and 8 years, respectively. Of the 13 survivors, 6 never received RT; their intellectual outcome did not differ significantly in those children than in those without RT. CONCLUSIONS Our results confirm poor rates of event-free survival and overall survival for up-front chemotherapy in infant ependymoma. No better neurocognitive outcome was demonstrated in the few survivors who never received RT.


Neuro-oncology | 2016

Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Maura Massimino; Rosalba Miceli; Felice Giangaspero; Luna Boschetti; Piergiorgio Modena; Manila Antonelli; Paolo Ferroli; Daniele Bertin; Emilia Pecori; Laura Valentini; Veronica Biassoni; Maria Luisa Garrè; Elisabetta Schiavello; Iacopo Sardi; Armando Cama; Elisabetta Viscardi; Giovanni Scarzello; Silvia Scoccianti; Maurizio Mascarin; Lucia Quaglietta; Giuseppe Cinalli; B. Diletto; Lorenzo Genitori; Paola Peretta; Anna Mussano; Annamaria Buccoliero; Giuseppina Calareso; Salvina Barra; Angela Mastronuzzi; Carlo Giussani

BACKGROUND This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). METHODS WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. RESULTS From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. CONCLUSIONS In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.

Collaboration


Dive into the Elisabetta Viscardi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Felice Giangaspero

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Massimo Conte

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maura Massimino

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Salvina Barra

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

Aurora Castellano

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge